Ionis Launches Tryngolza™ for FCS with Positive Phase 3 Data
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) has officially launched Tryngolza™ (olezarsen), a new RNA-targeted therapy for Familial Chylomicronemia Syndrome (FCS). Approved […]
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) has officially launched Tryngolza™ (olezarsen), a new RNA-targeted therapy for Familial Chylomicronemia Syndrome (FCS). Approved […]